The invention relates to process for the preparation of 2-amino-4-(4- fluorobenzylamino)-l-ethoxycarbonylaminobenzene generically known as Retigabine of the formula (I) and its pharmaceutically acceptable salts e.g. Formula IA, particularly to the modification over the prior art processes-I and II disclosed therein in US5384330. The modifications are depicted in the scheme I and scheme II respectively. Disclosed herein are also the novel processes for the preparation of intermediates of formulae M, N and O of the process-I and of formulae R, S, T of process-II, those are used for preparation of Retigabine of the formula I and its pharmaceutically acceptable salts thereof.
该发明涉及一种制备2-
氨基-4-(4-
氟苄胺基)-1-乙氧羰基
氨基苯的方法,通常被称为Retigabine,其分子式为(I),以及其药用可接受盐,例如分子式IA,特别是相对于美国专利US5384330中披露的先前工艺-I和II的改进。这些改进分别在方案I和方案II中描述。本文还披露了制备工艺-I的中间体M、N和O的新工艺,以及工艺-II的中间体R、S、T的分子式,这些中间体用于制备分子式I的Retigabine及其药用可接受盐。